ES2992544T3 - Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos - Google Patents

Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos Download PDF

Info

Publication number
ES2992544T3
ES2992544T3 ES17812341T ES17812341T ES2992544T3 ES 2992544 T3 ES2992544 T3 ES 2992544T3 ES 17812341 T ES17812341 T ES 17812341T ES 17812341 T ES17812341 T ES 17812341T ES 2992544 T3 ES2992544 T3 ES 2992544T3
Authority
ES
Spain
Prior art keywords
celastrol
cells
cell
viability
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17812341T
Other languages
English (en)
Spanish (es)
Inventor
Sarkissian Shant Der
Nicolas Noiseux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targa Biomedical Inc
Original Assignee
Targa Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targa Biomedical Inc filed Critical Targa Biomedical Inc
Application granted granted Critical
Publication of ES2992544T3 publication Critical patent/ES2992544T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES17812341T 2016-06-15 2017-06-15 Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos Active ES2992544T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662350258P 2016-06-15 2016-06-15
PCT/CA2017/000151 WO2017214709A1 (en) 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs

Publications (1)

Publication Number Publication Date
ES2992544T3 true ES2992544T3 (es) 2024-12-13

Family

ID=60663810

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17812341T Active ES2992544T3 (es) 2016-06-15 2017-06-15 Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos

Country Status (9)

Country Link
US (2) US11446265B2 (https=)
EP (1) EP3471733B1 (https=)
JP (3) JP7009463B2 (https=)
CN (2) CN109803664A (https=)
AU (1) AU2017285486B2 (https=)
CA (1) CA3027682A1 (https=)
DK (1) DK3471733T3 (https=)
ES (1) ES2992544T3 (https=)
WO (1) WO2017214709A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055817A1 (en) * 2017-09-14 2019-03-21 The Regents Of The University Of California EX VIVO CONSERVATION AND EXPANSION OF STEM CELLS
JP7404246B2 (ja) * 2018-02-14 2023-12-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー フォン・ヴィレブランド因子のレベルを調節する化合物、及び血液疾患の治療におけるそれらの使用
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
US20220023345A1 (en) * 2020-07-22 2022-01-27 Caladrius Biosciences, Inc. Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection
CN112375802A (zh) * 2020-11-06 2021-02-19 中国科学院城市环境研究所 评价白藜芦醇干预肺上皮细胞多环芳烃毒性效应的试剂或试剂盒及其应用和检测
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
WO2022212878A1 (en) * 2021-04-01 2022-10-06 The Regents Of The University Of California Human pluripotent stem cell-derived secretome as a biologic for prevention and treatment of neurodegenerative and apoptotic diseases
CN118634317B (zh) * 2024-08-16 2024-10-22 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1112181C (zh) 2000-05-26 2003-06-25 北京大学 雷公藤属植物提取物在制备预防和治疗神经系统疾病药上的应用
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100204093A1 (en) 2006-07-27 2010-08-12 University Of Florida Research Foundation, Inc Use of heat shock activators for tissue regeneration
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008063513A2 (en) 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
WO2009067245A2 (en) 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
CN101288671B (zh) 2008-04-17 2010-12-01 首都医科大学 雷公藤单体化合物在提高腺相关病毒载体介导的基因表达效率及其对神经退行性疾病的辅助治疗中的用途
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
CN101756956A (zh) 2009-03-25 2010-06-30 赵亚力 儿茶素在制备逆转录病毒整合酶抑制剂中的应用
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
CA3044998A1 (en) 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Also Published As

Publication number Publication date
US20230024103A1 (en) 2023-01-26
US20210169830A1 (en) 2021-06-10
US11446265B2 (en) 2022-09-20
JP2022062037A (ja) 2022-04-19
CN121313845A (zh) 2026-01-13
EP3471733A4 (en) 2020-02-05
WO2017214709A8 (en) 2018-12-13
AU2017285486A1 (en) 2019-02-07
EP3471733B1 (en) 2024-08-07
CN109803664A (zh) 2019-05-24
DK3471733T3 (da) 2024-10-14
JP7009463B2 (ja) 2022-01-25
EP3471733A1 (en) 2019-04-24
JP2019523784A (ja) 2019-08-29
CA3027682A1 (en) 2017-12-21
AU2017285486B2 (en) 2023-04-27
US12419849B2 (en) 2025-09-23
JP2024019483A (ja) 2024-02-09
WO2017214709A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
ES2992544T3 (es) Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos
Liesveld et al. Stem cell homing: From physiology to therapeutics
Gramignoli et al. Clinical hepatocyte transplantation: practical limits and possible solutions
ES2554492T3 (es) Microvesículas (MVs) derivadas de citoblastos de etapa adulta para uso en el tratamiento terapéutico de una enfermedad neoplásica.
Hou et al. C1q tumor necrosis factor-related protein-3 protects mesenchymal stem cells against hypoxia-and serum deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway
Li et al. Ultrasound‐targeted microbubble destruction improves the migration and homing of mesenchymal stem cells after myocardial infarction by upregulating SDF‐1/CXCR4: a pilot study
Tian et al. Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation
Barcia et al. Umbilical cord tissue–derived mesenchymal stromal cells maintain immunomodulatory and angiogenic potencies after cryopreservation and subsequent thawing
BR112013004700B1 (pt) uso de células precursoras de células-tronco mesenquimais (msc) cd271+
Wood et al. Distinct contribution of human cord blood‐derived endothelial colony forming cells to liver and gut in a fetal sheep model
Svalgaard et al. Cryopreservation of adipose-derived stromal/stem cells using 1–2% Me2SO (DMSO) in combination with pentaisomaltose: An effective and less toxic alternative to comparable freezing media
AU2017305067A1 (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
JP6114840B2 (ja) ヒトｃｄ３４陰性前駆細胞による免疫に媒介される細胞傷害性反応からの血管内皮の保護
Wrublewsky et al. The loss of pancreatic islet NADPH oxidase (NOX) 2 improves islet transplantation
Aum et al. Comparison of Stromal Vascular Fraction and Adipose‐Derived Stem Cells for Protection of Renal Function in a Rodent Model of Ischemic Acute Kidney Injury
Ellis et al. Adipose stem cell secretome markedly improves rodent heart and hiPSC-derived cardiomyocyte recovery from cardioplegic transport solution exposure
Urbanek et al. Cardioprotection by targeting the pool of resident and extracardiac progenitors
Lin et al. Human urine-derived stem cells from different donor sources ameliorate diabetic nephropathy in mice by activating autophagy and restoring mitochondrial function of podocyte
Wang et al. Administration of donor-derived nonexpanded adipose stromal vascular fraction attenuates ischemia-reperfusion injury in donation after cardiac death rat renal transplantation
HK40008604A (zh) 用於改善细胞、组织和器官的活力和功能的试剂、组合物和方法
Sokolova et al. Distribution of mesenchymal stem cells in the area of tissue inflammation after transplantation of the cell material via different routes
Kliuchnykova STEM CELLS AND THEIR PARACRINE FACTORS
Gonella Role of Liver Stem Cell-derived Extracellular Vesicles on ischemia-reperfusion injury in a murine liver experimental model
엄주민 Comparative study of autologous stromal vascular fraction and adipose-derived stem cells for recovery of renal function in a rat model of renal ischemia-reperfusion injury
CN121586768A (zh) 心肌细胞群、药物组合物、制备心肌细胞群的方法和心肌细胞球体